GlobeNewswire

Envonet Simplifies Searches for Corporate Environmental Financial Disclosures

Dela

Free web portal allows side-by-side comparisons of climate-related financial disclosures

AUSTIN, Texas, July 10, 2017 (GLOBE NEWSWIRE) -- EnvonetTM (www.envonet.com ) has launched a free online web portal to allow easy comparison of corporate environmental financial disclosures. Envonet is a global tool that enables users to quickly access environmental and climate-related financial disclosures that are often buried deep within lengthy financial filings.  Equally important, Envonet reveals where corporations have omitted information relevant to investors.

"Investors are urgently seeking more transparency from corporations about their material risks and risk management practices, particularly those related to climate change, but there are no simple tools to assist investors in collecting and assessing this information," said Greg Rogers, co-founder of Envonet and a long-time champion of corporate financial transparency. "And, when disclosures are compared side by side, the contrast between many European companies and their U.S. counterparts leaps off the page. For investors, it makes evident which corporations are treating climate change as a material financial risk and which are not."

Users can select several companies and compare their disclosures, side-by-side, such as the example provided in this news release with data from BP, Chevron, Exxon-Mobile and Shell. And with a single click, users can jump to the specific location of disclosures in a corporation's financial filings, where the information can be read in context.

Envonet displays climate-related disclosures in the areas of governance, strategy, risk management and performance measurement, found in mainstream financial filings (e.g., Form 10-Ks filed with the U.S. Securities Exchange Commission).  It also features environmental-related accounting disclosures for asset impairments and environmental and asset retirement obligations.  Envonet employs the framework developed by the Financial Stability Board (FSB) Task Force on Climate-related Financial Disclosures (TCFD), a private sector initiative chaired by Michael R. Bloomberg, and presented at last week's G20 Summit in Hamburg, Germany.  

Envonet Launches Free Web Portal for Environmental Financial Disclosures

Envonet initially features financial disclosures from 2016 year-end financial filings for 40 listed companies in the electric utility and oil and gas industries across the globe.  Utility companies include American Electric Power, CLP Holdings, Dominion Resources, DTE Energy, Edison International, Enel, Entergy, Eversource, Exelon, FirstEnergy, Fortis, Iberdrola, NextEra Energy, PG&E, Power Assets Holdings, PPL, Public Service Enterprise Group, Southern Company, SSE, and Xcel.

Oil and gas companies include Anadarko, Apache, BP, Canadian Natural Resources, Chevron, Concho Resources, ConocoPhillips, Devon Energy, Eni, EOG Resources, Exxon Mobil, Marathon, Occidental, Phillips 66, Pioneer Natural Resources, Royal Dutch Shell, Suncor Energy, Total, Valero, and Woodside Petroleum.

Envonet is designed for corporate financial officers, lawyers, auditors, investors, analysts, and regulators who prepare or compare financial disclosures pertaining to climate change, sustainability, impact investing, and ESG (environmental, social and governance). 

There is no cost to use the Envonet portal, but users must register at www.envonet.com for access to the database. A companion social media group on LinkedIn (Climate-Related Financial Disclosure) adds opportunity for discussion and collaborative learning. 

About Envonet: 
Envonet is a free collaborative project led by Greg Rogers, a leading expert in environmental financial reporting and author of Financial Reporting of Environmental Liability and Risk after Sarbanes-Oxley(Wiley).  Envonet is designed to be an extensive, global database of easily accessible corporate financial disclosures related to environmental and climate-related risk, liability and opportunity.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6094dbaa-7acb-4c5c-9da0-14de4d297430

Media Contact: Monty Hagler
mhagler@riversagency.com
001-336-553-1801



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Envonet via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum